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Abstract
 
We have studied the expression of members of the bcl-2
family in human breast cancer. The expression pattern of
these genes in breast cancer tissue samples was compared
with the expression pattern in normal breast epithelium. No
marked difference with regard to bcl-2 and bcl-xL expres-
sion was observed between normal breast epithelium and
cancer tissue. In contrast, bax-
 
a
 
, a splice variant of bax,
which promotes apoptosis, is expressed in high amounts in
normal breast epithelium, whereas only weak or no expres-
sion could be detected in 39 out of 40 cancer tissue samples
examined so far. Of interest, downregulation of bax-
 
a
 
 was
found in different histological subtypes. Furthermore, we
transfected bax-
 
a
 
 into breast cancer cell lines under the con-
trol of a tetracycline-dependent expression system. We were
able to demonstrate for the first time that induction of bax
expression in breast cancer cell lines restores sensitivity to-
wards both serum starvation and APO-I/Fas–triggered apop-
tosis and significantly reduces tumor growth in SCID mice.
Therefore, we propose that dysregulation of apoptosis might
contribute to the pathogenesis of breast cancer at least in
part due to an imbalance between members of the bcl-2 gene
family. (
 
J. Clin. Invest.
 
 1996. 97:2651–2659.) Key words:
APO-I/Fas 
 
•
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•
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•
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•
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Introduction
 
Apoptosis or programmed cell death plays an important role
in the regulation of tissue development, differentiation, and
homeostasis (1). Therefore, it is possible that dysregulation of
apoptosis contributes to the pathogenesis of cancer. This has
been shown in the case of malignant lymphomas where resis-
tance towards apoptosis is an important factor for tumor de-
velopment (2–6). Apoptosis can be distinguished biochemi-
cally and morphologically from necrosis by the following
criteria: (
 
a
 
) chromatin condensation, (
 
b
 
) membrane blebbing,
(
 
c
 
) the appearance of apoptotic bodies, and (
 
d
 
) fragmentation
of the genomic DNA (1). 
The role of apoptosis has been studied extensively in the
neuronal and lymphoid system during the past few years. It is
well documented that apoptosis occurs during antigen-medi-
ated selection processes within B and T cell ontogeny (7). In
epithelia, apoptotic mechanisms are not as precisely under-
stood as in the lymphoid system, although it has been reported
that apoptosis is involved in the regulation of epithelial devel-
opment and differentiation. For example, in hormone-depen-
dent tissues like mammary and prostate gland, apoptosis is
readily induced by hormone ablation and by treatment with
antiestrogens or antiandrogens (8, 9). Programmed cell death
is also observed during involution of the lactating breast (10,
11). Onset of cell death in these epithelia is accompanied by
the induction of multiple genes, e.g., 
 
TRMP-2
 
, 
 
stromelysin
 
, and
 
c-fos/jun D
 
 (9, 11, 12). Although little is known about the
mechanisms which regulate apoptosis in epithelia it is conceiv-
able, however, that defects in apoptosis-regulating genes are
involved in the pathogenesis of human carcinomas. This hy-
pothesis is supported by the fact that the tumor suppressor
gene product p53, which is frequently mutated or deleted in
different neoplasias including breast cancer, is involved in reg-
ulating apoptosis (13–17).
Apart from these genes, a well characterized molecule in-
volved in apoptosis is the APO-1/Fas (CD95) antigen (18, 19).
The CD95 antigen belongs to the TNF/NGF receptor super-
family (20, 21) and agonistic antibodies directed against this
antigen have been shown to induce apoptosis in normal and
malignant hematopoietic cells (18, 19, 22, 23). Recently, the
CD95 ligand has been cloned and was shown to induce apop-
tosis. CD95 expression has also been observed in a wide vari-
ety of epithelial tissues (24). In the normal mammary gland
CD95 is easily detected by immunohistochemistry on the aci-
nar and ductular epithelial cells. In breast carcinoma most tu-
mors are CD95 positive (24).
Another important regulator of apoptosis is the bcl-2 onco-
gene which was identified at t(14;18) chromosomal transloca-
tion breakpoints in the majority of follicular B cell lymphomas
(4). These translocations lead to juxtaposition of the bcl-2 gene
on chromosome 18 with the immunoglobulin heavy chain gene
(IgH) on chromosome 14 (5). Subsequent overexpression of
the bcl-2 gene renders the lymphoma cells resistant to apopto-
sis. Thus, dysregulation of apoptosis may be a causative event
in the evolution of B cell malignancies. In addition to lym-
phoid cells the bcl-2 gene is also expressed in other tissues,
such as mammary gland, prostate, complex differentiating epi-
thelia with long lived stem cells (intestine, skin), and fully dif-
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ferentiated noncycling cells like neurons (25). However, not all
long-lived cell types express the bcl-2 gene. In muscle cells and
in other tissues of mesodermal origin bcl-2 is not expressed.
Thus, bcl-2 gene expression seems to be restricted to tissues
which are able to undergo apoptosis.
Recently, two bcl-2–related genes were identified: bcl-x
and bax, both revealing significant sequence homology to bcl-2
(26, 27). Differential splicing of the bcl-x mRNA gives rise to a
short (bcl-xs) and to a long (bcl-xL) splice variant with differ-
ent functions: bcl-xL has an antiapoptotic effect whereas bcl-xs
suppresses bcl-2 function. In vivo, the long splice variant bcl-
xL is predominantly expressed in postmitotic quiescent cells,
whereas bcl-xs is expressed in tissues with a high cell turnover.
bax mRNA is also differentially spliced leading to bax-
 
a
 
 with a
length of 1 kb, bax-
 
b 
 
with a length of 1.5 kb, and bax-
 
g
 
 (27).
bax-
 
g
 
 lacks the small exon 2 (53 bp) resulting in a 
 
g
 
 form of
bax-
 
a
 
 or bax-
 
b
 
. Recently, another splice variant of bax has
been cloned, bax-
 
d
 
, lacking exon 3 (28). The function of the 
 
b
 
and 
 
d
 
 variants as well as the two 
 
g
 
 forms is still unclear. The
bax-
 
a
 
 mRNA encodes a bax protein that promotes apoptosis
due to its ability to form heterodimers with bcl-2 (27). Thus,
bcl-2, bcl-x, and bax are closely related factors which regulate
apoptosis.
It has not yet been determined whether bcl-2 or bcl-2 re-
lated genes play any role in the development of breast cancer.
It was reported that the bcl-2 gene is expressed in breast can-
cer specimens. However, similar levels of expression were
identified in normal tissues (29, 30). In other cases loss of bcl-2
gene expression was somewhat linked to markers of poor
prognosis (29). Others have reported that the predictive role
of bcl-2 expression in lymph node–negative patients was
mainly dependent on p53 expression (31).
Recently, we have found that bax-
 
a 
 
mRNA is expressed in
high amounts in normal breast tissue, whereas only weak or no
expression could be detected in breast cancer cell lines and in
10 different breast cancer tissue samples, which were all of the
ductal invasive type (32). Furthermore, we showed that in con-
trast to breast cancer–derived cell lines, which expressed low
levels of bax-
 
a
 
, normal epithelial cell lines displaying high
amounts of bax-
 
a
 
 were highly sensitive to induction of pro-
grammed cell death by both serum starvation and APO-1/Fas
(CD95) triggering. Therefore, in this study we were interested
whether our preliminary data on mRNA level can be con-
firmed by immunohistological and Northern blot analysis of a
larger number of histologically different breast cancer sam-
ples. To analyze the role of the bcl-2 gene family and of the
APO-1/Fas system in regulating apoptosis in epithelial cells
and to define its potential function in the development of
breast cancer we transfected bax-
 
a
 
 into breast cancer cell lines.
We were interested in whether induction of bax-
 
a
 
 expression
could restore sensitivity of serum starvation or APO-1/Fas–
mediated apoptosis in breast cancer cells and if so, whether
this has consequences for tumor growth in vivo.
 
Methods
 
Cells and tissues.
 
The following human cell lines were analyzed in
this study. The human breast cancer cell lines MCF-7 (estrogen re-
ceptor [ER]
 
1
 
 positive) and R30C (ER negative) (a generous gift from
Prof. Scherneck and Dr. Theile, Berlin, Germany). Breast cancer
samples and breast tissue samples from patients with fibrocystic dis-
ease were collected at surgery and processed as described previously
(33). Tumor-free (normal) breast tissue as determined by histology
was obtained from the same patients.
 
Culture conditions and reagents.
 
Cells were maintained in RPMI
1640 (Seromed-Biochrom, Hamburg, Germany), 10% heat-inacti-
vated FCS, 2 mM 
 
l
 
-glutamine (Gibco, Karlsruhe, Germany), and
penicillin-streptomycin (Seromed-Biochrom). Where indicated, cells
were cultured in the presence of tetracycline at a final concentration
of 2 
 
m
 
g/ml.
 
[
 
3
 
H]Thymidine incorporation assay.
 
5 
 
3
 
 10
 
4
 
 cells/well were cul-
tured in medium in 96-well round-bottom plates at 37
 
8
 
C for 48 h.
Where indicated, cells were cultured with culture medium in the pres-
ence of 1 
 
m
 
g/ml mAbs FII23c (22) or anti–APO-1 (22). The cells were
pulsed with 1 
 
m
 
Ci of [
 
3
 
H]thymidine (Amersham, Braunschweig, Ger-
many) after 2 d of culture and DNA synthesis was measured during
the last 16 h of culture. The cells were harvested onto glass filters and
the incorporated radioactivity was measured using a TopCount
counter (Canberra Packard, Frankfurt, Germany).
 
Determination of apoptotic cells by acridine orange staining.
 
After
serum depletion cultures were seeded at 3 
 
3
 
 10
 
5 
 
cells per 1 ml tissue
culture well in RPMI 1640, stained with acridine orange (5 
 
m
 
g/ml),
and observed by fluorescence microscopy. The number of frag-
mented nuclei, which reliably indicate apoptosis, was determined.
 
DNA fragmentation assay.
 
For DNA fragmentation analysis, cell
lysates were obtained by incubating a cell pellet containing 10
 
6
 
 cells in
20 ml lysis buffer (10 mM EDTA, 50 mM Tris, pH 8, 0.5% sarcosyl,
0.5 mg/ml proteinase K) for 1 h at 50
 
8
 
C. After addition of 5 ml of
RNase (1 mg/ml) and another incubation for 1 h at 50
 
8
 
C, lysates were
electrophoresed in a 2% agarose gel containing ethidium bromide.
The gel was run in a solution containing 26 mM Na
 
2
 
HPO
 
4
 
, 33 mM
NaH
 
2
 
PO
 
4
 
, 10 mM EDTA, and photographed under ultraviolet illumi-
nation.
 
Stable breast cancer cell lines R30C and MCF-7 expressing induc-
ible bax-
 
a
 
.
 
In the first step the plasmid pUHD 15-1 (34) containing
the tetracycline repressor gene fused with the viral VP16 coding re-
gion was linearized with ScaI, cotransfected with the resistance plas-
mid pUC18 (puromycin resistance) (Boehringer Mannheim, Mann-
heim, Germany), and selected for stable R30C and MCF-7 cell lines.
The bax-
 
a
 
 full-length cDNA was derived from RT-PCR (see be-
low). PCR fragments were sequenced and cloned into the expression
plasmid pUHD 10-3 (34). This plasmid was cotransfected with the re-
sistance plasmid pKEX (hygromycin resistance) (35) in a second step
into the stable cell lines.
Modulation of bax-
 
a
 
 expression was induced by incubating the
cells in medium with (2 
 
m
 
g/ml) or without tetracycline. Additionally,
using the same protocol, mock transfectants containing no insert in
pUHD 10-3 were generated.
 
mRNA preparation and Northern blotting.
 
RNA preparation was
performed using the guanidium isothiocyanate (GITC)/CsCl method.
Briefly, cells or tissue were lysed with GITC solution (4 M GITC,
20 mM sodium acetate, pH 5.2, 0.1 mM DTT, 0.5% sarcosyl [Sigma
Chemicals, Grünwald, Germany]). The resulting GITC cell lysate was
layered on top of a CsCl cushion (5.7 M, 100 mM EDTA). After ul-
tracentrifugation at 150,000 
 
g
 
 for 23 h at 18
 
8
 
C the RNA pellet was re-
suspended in Tris-EDTA (Tris 10 mM, EDTA 5 mM, pH 7.4) and
precipitated by 3 M sodium acetate and ethanol at 
 
2
 
80
 
8
 
C for 30 min.
10 
 
m
 
g of RNA was loaded onto a 1.2% agarose/1.1% formaldehyde
gel and separated electrophoretically. Northern transfer of RNA to
nylon membrane was performed by vacuum blotting (Appligene).
After prehybridization (50% deionized formamide, 0.6 M NaCl,
0.04 M NaH
 
2
 
PO
 
4
 
, pH 7.4, 4 mM EDTA, 1% SDS, 100 
 
m
 
g/ml herring
sperm DNA) at 42
 
8
 
C for 4–16 h, blots were hybridized for 20 h with a
 
32
 
P-random prime labeled probe.
 
RT-PCR analysis and human cDNA probes.
 
Total RNA was ex-
tracted from cells and tissues as described above. Purification of
poly(A)
 
1
 
 RNA from 10 
 
m
 
g of total RNA was performed using the
Dynabead mRNA purification kit (Dynal, Oslo, Norway). Detection
 
1. 
 
Abbreviation used in this paper:
 
 ER, estrogen receptor.
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of mRNA by PCR was performed as described (36) using a Geneamp
RNA PCR kit (Perkin Elmer-Cetus, Überlingen, Germany) and a
thermocycler (Bachhofer, Reutlingen, Germany) according to the
PCR protocol. In brief, 10 ng of poly(A)
 
1
 
 RNA was used per experi-
ment and 30 cycles were performed (conditions per cycle: 40 s at
94
 
8
 
C, 60 s at 60
 
8
 
C, 40 s at 72
 
8
 
C). bcl-x, bcl-2, and bax PCR products
were cloned, sequenced, and subsequently used as cDNA probes for
Northern blot hybridization as described before (32). Full-length bax
cDNA was generated for expression experiments (see above).
To distinguish the bcl-x splice variants, poly(A)
 
1
 
 RNA from the
various cells and tissues was analyzed by RT-PCR. Up- and down-
stream primers were used to amplify bcl-xL and bcl-xs simultaneously
(upstream: 5
 
9
 
-TTGGACAATGGACTGGTTGA-3
 
9
 
; downstream:
5
 
9
 
-GTAGAGTGGATGGTCAGTG-3
 
9
 
) resulting in bands of 780 and
591 bp, respectively. bcl-2 was amplified using the following primers:
upstream: 5
 
9
 
-GGTGCCACCTGTGGTCCACCTG-3
 
9
 
, downstream:
5
 
9
 
-CTTCACTTGTGGCCCAGATAGG-3
 
9
 
 (resulting fragment length:
459 bp). bax-
 
a
 
 was amplified using the following primers: upstream:
5
 
9
 
-CCGGAATTCCGGATGGACGGGTCCGGGGAGCAG-3
 
9
 
,
downstream: 5
 
9
 
-TGCTCTAGAGCATCAGCCCATCTTCTTCCAG-
3
 
9
 
 (resulting fragment length: 579 bp). 
 
b
 
-actin was amplified using the
following primers: upstream: 5
 
9
 
-GAGCTGCGTGTGGCTCCCG-
AGG-3
 
9
 
 (resulting fragment length: 579 bp), downstream: 5
 
9
 
-CG-
CAGGATGGCATGGGGGAGGGCATACCCC-3
 
9
 
 (resulting frag-
ment length: 246 bp).
 
Protein preparation and immunoblotting.
 
Cell lysates were ob-
tained by incubating 10
 
7
 
 cells in lysis buffer (20 mM Tris-acetate, pH
7, 10 mM sodium-glycerophosphate, 50 mM sodium-fluoride, 5 mM
sodium-pyrophosphate, 1% Triton X-100, 0.1 mM EDTA, 1 mM
EGTA, 0.2 mM PMSF, 0.27 mM sucrose, 2 
 
m
 
g/ml leupeptin) for 30
min at 4
 
8
 
C. Thereafter lysates were centrifuged for 10 min (1,000 
 
g
 
).
The supernatant containing the membrane and cytoplasmic proteins
was precipitated using methanol/chloroform. 20 
 
m
 
g protein per lane
was electrophoretically separated using 12% SDS-PAGE. Detection
of bcl-2, bax, or tubulin protein by immunoblotting or immunohistol-
ogy (see below) was performed using the following antibodies: anti-
bax: polyclonal rabbit antiserum purchased from Santa Cruz Biotech-
Figure 1. mRNA expression of bcl-2, bcl-xL, 
bcl-xs, and bax in breast cancer tissue. (a) 
Shown is Northern blot hybridization of 
three different normal tissue samples (lanes 
1–3) and 15 different cancer tissue samples 
(lanes 1–15). Normal tissue (lanes 1–3) was 
derived from nonmalignant areas (as defined 
by histology) of the same breast as the malig-
nant tissue (lanes 1–3). Cancer-derived cell 
lines show low bax expression. In cancer tis-
sue samples no bax signal can be detected. In 
contrast, strong expression is found in all 
normal cell lines and tissues. bcl-2 and bcl-x 
are expressed in all tissue samples, b-actin 
served as a control. Note the shorter exposi-
tion time of the right b-actin blot (lanes 10–
15). (b) RT-PCR analysis of bcl-x. PCR 
primers were designed to detect the long 
(bcl-xL) and short (bcl-xs) splice variant si-
multaneously generating PCR bands of 780 
and 591 bp, respectively. The same tissue 
samples (lanes 1–15) as in a were analyzed. 
bcl-xs mRNA could only be detected in 
R30C cells. (c) Northern data on normal 
(lanes 1–3) and malignant (lanes 1–15) pri-
mary tissue were quantified by using an In-
stant Imager (Canberra Packard). The ratio 
of bax/actin, bcl-2/actin, and bcl-x/actin was 
determined.
Table I. Expression of Members of the bcl-2 Family in Normal 
and Malignant Breast Tissue
Histology bcl-2 bcl-xL bcl-xs bax-a
Ductal invasive 31/33 33/33 0/33 1/33
Lobular 2/2 2/2 0/2 0/2
Intraductal 4/4 4/4 0/4 0/4
Mucinous 1/1 1/1 0/1 0/1
Fibrocystic 4/4 4/4 0/4 4/4
Normal 6/6 6/6 0/6 6/6
Northern blot and RT-PCR data on bcl-2, bcl-xL, bcl-xs, and bax ex-
pression are summarized (see also Fig. 1). RT-PCR was used to be able 
to discriminate between the long (bcl-xL) and short (bcl-xs) splice vari-
ant of bcL-x (see also Fig. 1 b). bax expression was additionally deter-
mined by immunohistology (see also Fig. 2). 40 samples derived from 
breast cancer tissue, four cases of fibrocystic disease and tumor-free tis-
sue (as defined by histology) of six different cancer samples were ana-
lyzed. Malignant tissue samples included different histological subtypes: 
33 ductal invasive, 2 lobular invasive, 1 mucinous, and 4 intraductal (in 
situ carcinoma) carcinomas. Comparable amounts of bcl-2 and bcl-xL 
expression could be detected in normal and malignant breast epithe-
lium, whereas bcl-xs expression could not be detected. No or only weak 
bcl-2 expression was detected in two cancer samples of the ductal inva-
sive type, whereas bcl-xL expression could be detected in every tissue 
sample examined so far. Strong expression of bax is detectable in nor-
mal breast epithelium, whereas only partial, weak, or no expression 
could be found in 39 out of 40 different cancer tissue samples examined 
so far. Partial bax expression was observed in 23 tumor samples. In 
these cases 5–20% of the invasive component was bax positive. About 
the same ratio between positive and negative cells could be observed in 
noninvasive components (in situ carcinoma). 29 tumor samples con-
tained bax-positive cells as an internal control (normal epithelium, ma-
lignant cells, or nonepithelial cells). Note that the seven cases that did 
not contain such internal control cells were also devoid of histologically 
normal tissue.
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Tween 20) for 40 min at room temperature. Bands were visualized us-
ing chromogenic substrates NBT/BCIP (Roth, Karlsruhe, Germany).
Immunohistology. From the quick-frozen tissues frozen sections
of z 4–6 mm in thickness were air dried, fixed in acetone for 10 min at
room temperature, and immunostained immediately or stored at 2208C.
Antibodies against bax or bcl-2 are described above and were used
for immunohistology. For antibody staining, an alkaline phosphatase/
anti–alkaline phosphatase staining procedure was applied as described
before (38). The sections were counterstained with hematoxylin.
nology, Inc. (Santa Cruz, CA); anti–bcl-2: monoclonal mouse anti-
body purchased from Sigma Chemicals; anti-tubulin: monoclonal rat
antibody purchased from Serotec (Wiesbaden, Germany). After
transfer to nitrocellulose and blocking (3% BSA 13 PBS, overnight
48C), filters were incubated with antiserum (dilution 1:200 [anti-bax],
1:1,000 [anti–bcl-2 or anti–bcl-x] in 13 PBS, 1% BSA, 0.5% Tween
20). Thereafter filters were incubated with alkaline phosphatase–con-
jugated goat anti–rabbit or goat anti–mouse antibody (Dianova,
Hamburg, Germany; dilution 1:7,500 in 13 PBS, 1% BSA, 0.5%
Figure 2. Immunohistological analysis of bax expression in normal and malignant breast epithelium. Shown is bax and bcl-2 staining of frozen 
tissue sections. Anti-bax or anti–bcl-2 staining is visualized via an indirect alkaline phosphatase method. A faint hematoxylin staining serves as 
counterstain. (a) Lobulo-alveolar structure normal breast epithelium. Strong bax staining is detectable in nearly every epithelial cell. (b) Malig-
nant epithelium of a ductal invasive carcinoma. No bax expression is detectable in the majority of the cells. (c) Ductal epithelium of a patient 
with fibrocystic disease. Strong bax staining is detectable in every epithelial cell. (d) Malignant epithelium of a ductal invasive carcinoma. Strong 
bcl-2 staining is detectable. (e) Malignant epithelium of a ductal invasive carcinoma with an intraductal portion. No bax expression is detectable.
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Expression of p53 was evaluated according to previously de-
scribed methods (39) using a monoclonal anti-p53 antibody (PAb1801;
Cambridge Research Biochemicals, Wilmington, DE).
Xenotransplantation of cells into SCID mice. R30C and MCF-7
cells (106) were injected subcutaneously into C.B.-17 scid/scid mice.
The mice were obtained from our own breeding colony and were
kept in isolators under stringent conditions in the central animal labo-
ratory of the Max Delbrück Center for Molecular Medicine. Microbi-
ological controls were performed regularly by addition of sterile sen-
tinel animals to the colony. Tumors were measured in two
dimensions, length (a) and width (b), by means of calipers in millime-
ters. Tumor volume (V) was calculated according to V 5 ab2/2, where
a is the longer of the two measurements.
Results
bcl-x and bcl-2 are expressed in normal and malignant breast
epithelium. Expression of bcl-x and bcl-2 was studied in 40 dif-
ferent breast cancer tissue samples and 10 nonmalignant breast
tissue samples by Northern blot analysis. Nonmalignant tissue
samples included four cases of fibrocystic disease and tumor-
free tissue of six different cancer samples. To discriminate be-
tween the two bcl-x splice variants we additionally performed
RT-PCR analysis. No major difference was observed with re-
gard to bcl-2 or bcl-xL expression between normal and malig-
nant breast tissue (Fig. 1 and Table I). No or only weak bcl-2
expression could be detected in two cancer samples of the duc-
tal invasive type (Table I). bcl-xs expression could not be de-
tected, neither in normal nor in malignant breast epithelia.
Table II. Comparison between mRNA Expression Levels of Members of the bcl-2 Family in Breast Cancer Tissue and Other 
Tumor/Patient Characteristics
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
bax/actin , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01 , 0.01
bcl-2/actin 0.5 0.2 1.5 0.2 0.2 0.15 0.4 0.2 0.2 1 0.5 1.5 1 1 1.5
bcl-x/actin 1 1 1 0.4 0.4 0.1 0.3 5 0.4 1 0.5 1.5 2 0.5 0.5
Postmenopausal 1 2 1 1 2 1 2 1 2 2 2 2 2 1 1
ER 2 2 1 2 1 2 2 1 1 2 1 2 2 2 1
PR 1 1 2 1 2 2 2 2 1 2 2 2 2 1 1
p53 2 2 2 1 2 2 2 2 1 1 2 2 1 2 2
Quantitative mRNA analysis of bcl-2, bcl-x, and bax expression of 15 patients is also shown in Fig. 1 c. PR, progesterone receptor. p53 status was de-
termined by immunohistology as described in Methods.
Figure 3. Inducible expression of bax-a in breast cancer cell lines. 
Shown is Western blot analysis of bax-a protein expression in MCF-7 
and R30C breast cancer cells. Mock transfectants and stable bax 
clones, which are under transcriptional control of a tetracycline-
dependent repressor, were generated as described in Methods. Cells 
were cultured in the presence or absence of tetracycline. Protein was 
extracted 24 h after tetracycline withdrawal. Equal amounts of pro-
tein (20 mg) were loaded on each lane. Strong induction of bax-a pro-
tein can be detected after tetracycline withdrawal, whereas in the 
presence of tetracycline bax expression is completely repressed. Tu-
bulin served as a control.
Figure 4. Induction of 
apoptosis in bax-
expressing R30C and 
MCF-7 clones after se-
rum starvation. Un-
transfected (R30C), 
mock-transfected 
(R30C mock), or bax-
transfected cells (R30C 
bax, MCF-7 bax) were 
cultured in the pres-
ence or absence of tet-
racycline (1/2 Tet) for 
prolonged time periods 
after serum starvation. 
(a) Apoptosis was as-
sayed morphologically 
by staining the nuclei 
with acridine orange at 
days 1, 2, 4, 6, 8, and 10. 
The number of frag-
mented nuclei (indicat-
ing apoptosis) from 100 
cells was determined 
and expressed as a per-
centage of apoptotic 
cells. The mean and 
standard deviation of 
four independent experiments is shown. Induction of bax by tetracy-
cline withdrawal strongly increases sensitivity towards apoptosis in 
R30C breast cancer cells. Apoptosis sensitivity was comparable with 
that found in cultured cells which were derived from nonmalignant 
breast epithelium (32). Filled circles, R30C; filled squares, R30C 
mock; open circles, R30C bax 1 Tet; filled triangles, R30C bax 2 Tet. 
(b) Detection of apoptosis by DNA fragmentation in R30C and 
MCF-7 cells. Inducible bax transfectants of R30C or MCF-7 were cul-
tured in the presence (1) or absence (2) of 2 mg/ml tetracycline. 24 h 
after tetracycline withdrawal serum was depleted. Agarose gel elec-
trophoresis of DNA extracted from R30C and MCF-7 cells was per-
formed 3 d after serum starvation. Mock transfected R30C and MCF-7 
cells served as a control.
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Additionally, we quantified Northern data of 15 patients
using an Instant Imager. The ratio of bax/actin, bcl-2/actin, and
bcl-x/actin was determined (Fig. 1 c). Quantification revealed
differences in bcl-2 and bcl-x mRNA expression levels be-
tween different tumor samples. However, different bcl-2 and
bcl-x expression levels could also be observed in normal breast
tissue in a similar range as in tumor tissue. There are some tu-
mors which showed bcl-2 and bcl-x expression levels beneath
the range of normal tissue. One tumor showed elevated bcl-x
expression compared with normal tissue. However, the major-
ity of tumor tissue samples analyzed so far revealed similar
amounts of bcl-2 or bcl-xL compared with normal mammary
tissue.
bax-a is strongly expressed in normal breast epithelium but
is downregulated in malignant epithelia. Expression of bax
mRNA and protein was studied in normal and malignant
breast epithelium (see above) by Northern blot hybridization
and immunohistology. Nonmalignant tissue samples included
four cases of fibrocystic disease and tumor-free tissue of six
different cancer samples. bax-a was expressed in high amounts
in normal breast epithelium, whereas only partial, weak, or no
expression could be detected in the vast majority of cancer tis-
sue samples examined so far (Figs. 1 and 2, all tissue data are
summarized in Table I). Thus, data on downregulation of bax
expression on mRNA level in breast cancer tissue could be
confirmed by immunohistological analysis.
In addition to the 1-kb splice variant which encodes the
functional death-promoting bax-a protein, a longer 1.5-kb
mRNA which is consistent with bax-b could be detected in
normal tissue. The function of this variant which is probably
not translated into protein is unknown.
Only 1 out of 40 cancer tissue samples examined so far re-
vealed a bax expression level comparable with that found in
normal epithelium (Table I). Interestingly, downregulation of
bax-a was found in different histological subtypes, including
ductal invasive, lobular, mucinous, and even intraductal (carci-
noma in situ) carcinomas (Table I and Fig. 2).
It has been reported that p53 might be involved in the tran-
scriptional regulation of bax expression (15). Furthermore, it
has been published that estrogens may modulate bcl-2 expres-
sion in breast tissue (40). Therefore, we provided data on the
hormonal status (pre- versus postmenopausal, ER, progester-
one receptor) and the p53 status and compared these data with
bcl-2, bcl-x, and bax mRNA expression levels in different
breast cancer tissues (Table II). Differences in bcl-2 and bcl-x
mRNA expression levels as well as the strong downregulation
of bax in breast cancer tissue did not correlate with the hor-
monal status or the p53 status. The lack of a correlation be-
tween p53 status and bax expression was also reported by Kra-
jewski et al. (41).
Induction of bax-a expression in breast cancer cell lines can
restore sensitivity of serum starvation or APO-I/Fas–mediated
apoptosis. Recently, we have shown that low bax-a expression
in breast cancer cell lines correlates with resistance towards
apoptosis (32). In contrast to malignant cell lines, which ex-
press low levels of bax-a, nonmalignant epithelial cell lines dis-
playing high amounts of bax-a were highly sensitive to induc-
tion of programmed cell death by both serum starvation and
APO-I/Fas (CD95) triggering (32). To test whether low bax-a
expression in breast cancer cell lines is due to apoptosis resis-
tance we transfected bax cDNA under the control of a tetracy-
cline-regulated expression system into these cells. As shown in
Fig. 3, withdrawal of tetracycline led to strong induction of bax
expression in R30C and MCF-7 cells. In the presence of tetra-
cycline bax expression was completely repressed. As depicted
in Fig. 4, a and b, induction of bax-a expression strongly in-
creases sensitivity towards apoptosis induced by serum starva-
tion. bax-expressing cells started to die within 2 d, whereas
clones which were devoid of bax expression showed prolonged
resistance to apoptosis at least until day 10 after serum starva-
Figure 5. Induction of apoptosis in bax 
expressing R30C and MCF-7 clones after 
APO-1/Fas triggering. (a) Antiprolifera-
tive effect of anti–APO-1 on R30C and 
MCF-7 breast cancer cells. Inducible bax 
transfectants of R30C or MCF-7 were 
cultured in the presence (1) or absence 
(2) of 2 mg/ml tetracycline. 24 h after tet-
racycline withdrawal 1 mg/ml anti–APO-1 
or FII23c was added to the culture me-
dium. [3H]Thymidine incorporation assay 
was performed 48 h after APO-1/Fas trig-
gering as described in Methods. The 
mean and standard deviation of four in-
dependent experiments is indicated. (b) 
Detection of apoptosis by DNA fragmen-
tation in R30C and MCF-7 cells. Induc-
ible bax transfectants of R30C or MCF-7 
were cultured in the presence (1) or ab-
sence (2) of 2 mg/ml tetracycline. 24 h af-
ter tetracycline withdrawal 1 mg/ml anti–
APO-1 was added to the culture medium. 
Agarose gel electrophoresis of DNA ex-
tracted from R30C and MCF-7 cells was 
performed 2 d after APO-1/FAS trigger-
ing. DNA fragmentation can only be ob-
served in bax-expressing MCF-7 cells af-
ter tetracycline withdrawal.
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ated apoptosis in R30C cells, indicating that bax expression is
important but not sufficient to confer APO-1/Fas sensitivity.
Thus, we showed that induction of bax-a can restore sensi-
tivity towards different apoptotic stimuli in breast cancer cell
lines.
Induction of bax-a expression reduces tumor growth in
SCID mice. To test the effects of bax expression on tumor
growth in vivo, we transplanted bax-expressing clones of the
breast cancer cell lines R30C and MCF-7 into SCID mice. As
shown in Fig. 6, bax-expressing breast cancer cells are still tum-
origenic. However, tumor size and velocity of tumor growth
are significantly reduced compared with mock transfected or
untransfected clones.
Discussion
Apoptosis is a physiological process that contributes to the reg-
ulation of development, differentiation, and growth in various
tissues. Therefore, dysregulation of apoptosis might be involved
in pathogenesis of neoplasias. This is particularly well docu-
mented for malignant lymphomas where bcl-2 overexpression
was shown to be involved in malignant transformation (42).
In carcinomas, the role of bcl-2 in tumorigenesis is still un-
clear. We and others (29, 32) have observed bcl-2 expression in
breast cancer without a marked difference to normal epithe-
lium. Some tumors failed to express bcl-2, which surprisingly
correlated with markers of poor prognosis (29). Similar results
were obtained for non–small cell lung carcinoma (43). bcl-xL
expression appeared to be elevated in some tumors and re-
duced in others. However, in accordance with the data con-
cerning bcl-2, the majority of tumor tissue samples analyzed so
far revealed similar amounts of bcl-xL compared with normal
mammary tissue. bcl-xs expression could not be detected, nei-
ther in normal nor in malignant breast epithelia.
In contrast, analysis of bax expression revealed a marked
difference between normal and cancer epithelia: strong ex-
pression of bax-a was observed in normal epithelial cells and
breast tissue, whereas only weak or partial expression was
found in their malignant counterparts. Low levels of bax in
conjunction with normal bcl-2 and bcl-x levels might disrupt
the cellular homeostasis leading to an accumulation of cells,
which might thus become susceptible for secondary mutagenic
events resulting in malignant transformation. Since differences
in bcl-x and bcl-2 expression between normal and some malig-
nant tissue samples could be found, we cannot exclude that in
some cases deregulation of bcl-2 or bcl-x expression might also
modulate apoptosis in breast cancer cells. However, compared
with the striking change in bax expression, these differences
are presumably of minor significance.
As low bax expression is still found in some tumors and cell
lines, weak bax expression is probably not due to gross genetic
alterations of the bax locus itself. It is conceivable that other
genes involved in malignant transformation might cause down-
regulation of bax. p53 itself or p53-regulated genes could be
candidates, because p53 has also been shown to be a regulator
of apoptosis and a direct transcriptional activator of the human
bax gene (13–15, 44). Thus, constitutive expression of bcl-2
and bcl-xL and low expression of bax might at least in part be
due to a loss of function of p53. However, since we found no
correlation between bax downregulation and p53 status, we as-
sume that besides p53 further genes are involved in the down-
regulation of bax expression in malignant breast epithelium.
tion. Apoptosis sensitivity in bax-expressing cancer cell lines
was comparable with that found in HMEC and HBL-100 cells
(32), which were derived from normal (nonmalignant) human
breast epithelium.
Furthermore, we could show that induction of bax-a in the
breast cancer cell line MCF-7 strongly increases sensitivity to-
wards APO-1/Fas–mediated apoptosis (Fig. 5, a and b). A
weak apoptotic effect of APO-1/Fas triggering (30% growth
inhibition) could also be observed in cells which were devoid
of detectable bax expression levels. In contrast, induction of
bax expression did not affect resistance to APO-1/Fas–medi-
Figure 6. Tumor growth of bax-expressing R30C and MCF-7 clones 
in SCID mice. Shown is tumor growth of five different bax-expressing 
and five different mock clones of R30C and MCF-7 breast cancer 
cells. Untransfected clones were included. Each cell clone was trans-
planted on six different animals. Animals were challenged with equal 
cell numbers (106) at day 0. Tumor size was determined at different 
time points as described in Methods. Mean and standard deviation of 
30 (R30C bax, R30C mock, MCF-7 bax, MCF-7 mock) or 6 (R30C, 
MCF-7) independently performed experiments are shown. Symbols 
in a: filled circles, R30C bax; filled squares, R30C mock; open circles, 
R30C. Symbols in b: filled circles, MCF-7 bax; filled squares, MCF-7 
mock; open circles, MCF-7.
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The CD95 antigen and its role in apoptosis have been stud-
ied mainly in normal and malignant lymphoid cells. However,
CD95 can also be detected in many epithelial tissues (24). In
these experiments we provide evidence that, as in lymphoid
cells, expression of CD95 does not necessarily correlate with
sensitivity towards apoptosis (45). In B-CLL cells an inverse
correlation between bcl-2 expression and sensitivity to CD95-
mediated apoptosis was found (45). In contrast, sensitivity to
CD95-mediated apoptosis does not correlate with bcl-2 ex-
pression in prostatic adenocarcinoma or colon carcinoma cell
lines (46) and overexpression of bcl-2 is able to confer only
partial protection against CD95-mediated apoptosis (47).
Thus, additional genes have to be involved in regulation of
CD95-triggered apoptosis. Recently, it has been shown that
coexpression of bcl-2 and bag-1, another apoptosis-regulating
gene, which does not belong to the bcl-2 gene family, com-
pletely protects from CD95-mediated apoptosis (48).
Recently, we have shown that low bax-a expression in
breast cancer cell lines correlates with resistance towards apop-
tosis (32). In contrast to malignant cell lines, which express low
levels of bax-a, nonmalignant epithelial cell lines displaying
high amounts of bax-a were highly sensitive to induction of
programmed cell death by both serum starvation and APO-I/
Fas (CD95) triggering. To test whether low bax-a expression
in breast cancer cell lines is due to apoptosis resistance, we
transfected bax cDNA under the control of a tetracycline-reg-
ulated expression system into these cells. We were able to
show that induction of bax expression in breast cancer cell
lines restores sensitivity towards both serum starvation or
CD95-induced apoptosis. Thus, we were able to demonstrate
for the first time that bax can confer sensitivity to different
apoptotic stimuli, e.g., serum starvation or CD95 triggering.
Therefore, it appears that the bcl-2 family constitutes a major
death checkpoint integrating different apoptotic pathways.
The decreased sensitivity of breast carcinoma cell lines to-
wards CD95-mediated apoptosis furthermore indicates a po-
tential role of an intact CD95 apoptosis signaling pathway in
the homeostasis of normal breast epithelium.
Consistent with our observations, another recent paper
demonstrated reduced bax immunostaining in breast cancers
and found correlations with poor responses to chemotherapy
and patient survival (41). The authors arbitrarily defined bax-
negative cases as those in which the vast majority of the tumor
cells were unstained (, 10%), with bax-positive cases repre-
senting all others (. 10%), and found that complete loss
(, 10%) of bax expression is correlated with poor response
rates to chemotherapy and shorter survival in women with
metastatic breast adenocarcinoma. Since antineoplastic drugs
can kill at least in part tumor cells via apoptosis, our functional
data, showing that induction of the bax gene can restore sensi-
tivity to different apoptotic stimuli in cultured breast cancer
cells, might serve as an explanation for this correlation. In ad-
dition, the authors report that they could not detect reduced
bax expression in in situ carcinomas, which is in contrast to our
data. This contradiction might be due to different immunohis-
tological staining techniques.
To test whether induction of bax-a affects tumor growth in
vivo, we transplanted a bax-expressing breast cancer cell line
into SCID mice. Although tumor growth could not be com-
pletely prevented, we were able to show that bax expression
led to a significant reduction of tumor growth. This finding
provides further evidence that dysregulation of apoptosis, at
least in part due to downregulation of bax-a expression, con-
tributes to the pathogenesis of breast cancer.
In summary, we could show the following: (a) bax-a ex-
pression is downregulated in malignant breast epithelium in
comparison to normal epithelium; (b) induction of bax-a re-
stores sensitivity towards serum starvation or APO-1/Fas–
mediated apoptosis in breast cancer cell lines; and (c) induc-
tion of bax-a reduces tumor growth in SCID mice. Therefore,
we propose that the bcl-2 family and APO-1/Fas are involved
in the regulation of tissue homeostasis not only of the lym-
phoid system but also of epithelial cells. An imbalance within
the bcl-2 family members leads to dysregulation of apoptosis
and therefore might contribute to the pathogenesis of breast
cancer.
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